93 related articles for article (PubMed ID: 2428937)
21. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
22. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat.
Ambrosio S; Blesa R; Mintenig GM; Palacios-Araus L; Mahy N; Gual A
Toxicol Lett; 1988 Nov; 44(1-2):1-6. PubMed ID: 3263717
[TBL] [Abstract][Full Text] [Related]
23. Primate model of Parkinson's disease: alterations in multiple opioid systems in the basal ganglia.
Zamir N; Skofitsch G; Bannon MJ; Helke CJ; Kopin IJ; Jacobowitz DM
Brain Res; 1984 Nov; 322(2):356-60. PubMed ID: 6150750
[TBL] [Abstract][Full Text] [Related]
24. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
Kunikowska G; Jenner P
Brain Res; 2003 Apr; 968(2):206-18. PubMed ID: 12663090
[TBL] [Abstract][Full Text] [Related]
25. Localization of nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/Bl mice.
Chen LW; Zhang JP; Kwok-Yan Shum D; Chan YS
J Comp Neurol; 2006 Aug; 497(6):898-909. PubMed ID: 16802332
[TBL] [Abstract][Full Text] [Related]
26. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
Fernandez A; de Ceballos ML; Rose S; Jenner P; Marsden CD
Brain; 1996 Jun; 119 ( Pt 3)():823-30. PubMed ID: 8673494
[TBL] [Abstract][Full Text] [Related]
27. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
Ando K; Maeda J; Inaji M; Okauchi T; Obayashi S; Higuchi M; Suhara T; Tanioka Y
Psychopharmacology (Berl); 2008 Jan; 195(4):509-16. PubMed ID: 17879087
[TBL] [Abstract][Full Text] [Related]
28. Increased dopamine turnover in the putamen after MPTP treatment in common marmosets.
Nomoto M; Iwata SI; Kaseda S; Fukuda T; Nakagawa S
Brain Res; 1997 Sep; 767(2):235-8. PubMed ID: 9367253
[TBL] [Abstract][Full Text] [Related]
29. Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.
Feher M; Gaszner B; Tamas A; Gil-Martinez AL; Fernandez-Villalba E; Herrero MT; Reglodi D
Neurotox Res; 2018 May; 33(4):702-715. PubMed ID: 29230633
[TBL] [Abstract][Full Text] [Related]
30. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
[TBL] [Abstract][Full Text] [Related]
31. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
32. Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms.
Dacko S; Schneider JS
Neurosci Lett; 1991 Jun; 127(1):49-52. PubMed ID: 1881617
[TBL] [Abstract][Full Text] [Related]
33. Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Close SP; Marriott AS; Pay S
Br J Pharmacol; 1985 Jun; 85(2):320-2. PubMed ID: 3928007
[TBL] [Abstract][Full Text] [Related]
34. The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Russ H; Henning K; Eckhardt H; Przuntek H
Arzneimittelforschung; 1985; 35(2):481-2. PubMed ID: 2581589
[TBL] [Abstract][Full Text] [Related]
35. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
36. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Di Paolo T; Bédard P; Daigle M; Boucher R
Brain Res; 1986 Aug; 379(2):286-93. PubMed ID: 2427166
[TBL] [Abstract][Full Text] [Related]
39. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM
Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359
[TBL] [Abstract][Full Text] [Related]
40. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
